Evidence map›Paper›PMID 30700319›Full record

ArticleBreast cancer research : BCR2019

Serum erythropoietin levels, breast cancer and breast cancer-initiating cells.

Kruttika Bhat, Kiri Sandler, Sara Duhachek-Muggy, Claudia Alli, Fei Cheng, Neda A Moatamed, Clara E Magyar, Lin Du, Gang Li, Susan McCloskey and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer research : BCR, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 16 citations in OpenAlex.

  1. Erythroid Cells as Full Participants in the Tumor Microenvironment.International journal of molecular sciences · 2023
    Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Kruttika BhatDepartment of Radiation Oncology, David Geffen School of Medicine at UCLA, 10833 Le Conte Ave, Los Angeles, CA, 90095-1714, USA.
Kiri SandlerDepartment of Radiation Oncology, David Geffen School of Medicine at UCLA, 10833 Le Conte Ave, Los Angeles, CA, 90095-1714, USA.
Sara Duhachek-MuggyDepartment of Radiation Oncology, David Geffen School of Medicine at UCLA, 10833 Le Conte Ave, Los Angeles, CA, 90095-1714, USA.
Claudia AlliDepartment of Radiation Oncology, David Geffen School of Medicine at UCLA, 10833 Le Conte Ave, Los Angeles, CA, 90095-1714, USA.
Fei ChengDepartment of Radiation Oncology, David Geffen School of Medicine at UCLA, 10833 Le Conte Ave, Los Angeles, CA, 90095-1714, USA.
Neda A MoatamedDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Clara E MagyarImage Analysis/Virtual Microscopy, Translational Pathology Core Laboratory, Department of Pathology and Laboratory Medicine, Los Angeles, CA, USA.
Lin DuDepartment of Biostatistics, School of Public Health at UCLA, Los Angeles, CA, USA.
Gang LiDepartment of Biostatistics, School of Public Health at UCLA, Los Angeles, CA, USA.
Susan McCloskeyDepartment of Radiation Oncology, David Geffen School of Medicine at UCLA, 10833 Le Conte Ave, Los Angeles, CA, 90095-1714, USA.
Erina VlashiDepartment of Radiation Oncology, David Geffen School of Medicine at UCLA, 10833 Le Conte Ave, Los Angeles, CA, 90095-1714, USA.
Frank PajonkDepartment of Radiation Oncology, David Geffen School of Medicine at UCLA, 10833 Le Conte Ave, Los Angeles, CA, 90095-1714, USA. pajonk@ucla.edu.
University of California, Los Angeles · USUCLA Jonsson Comprehensive Cancer Center

Funding

UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI David A. Nathanson · 2017 to 2026
$25.2M
Glioblastoma, Glioblastoma Stem Cells and RadiotherapyR01CA200234 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI PAJONK, FRANK · 2016 to 2020
$1.8M
Erythropoietin and Breast Cancer Stem CellsR01CA161294 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI PAJONK, FRANK · 2012 to 2016
$1.6M
The 26S Proteasome in Cancer Stem CellsR01CA137110 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI PAJONK, FRANK · 2009 to 2013
$1.6M
NCI NIH HHS CA137110NCI NIH HHS P50 CA211015NCI NIH HHS R01 CA161294NCI NIH HHS R01 CA200234
6 · The paper itself

Abstract

backgroundCancer is frequently associated with tumor-related anemia, and many chemotherapeutic agents impair hematopoiesis, leading to impaired quality of life for affected patients. The use of erythropoiesis-stimulating agents has come under scrutiny after prospective clinical trials using recombinant erythropoietin to correct anemia reported increased incidence of thromboembolic events and cancer-related deaths. Furthermore, previous preclinical reports indicated expansion of the pool of breast cancer-initiating cells when erythropoietin was combined with ionizing radiation.

methodsUsing four established breast cancer cell lines, we test the effects of recombinant human erythropoietin and the number of breast cancer-initiating cells in vitro and in vivo and study if recombinant human erythropoietin promotes the phenotype conversion of non-tumorigenic breast cancer cells into breast cancer-initiating cells. In a prospective study, we evaluate whether elevated endogenous serum erythropoietin levels correlate with increased numbers of tumor-initiating cells in a cohort of breast cancer patients who were scheduled to undergo radiation treatment.

resultsOur results indicate that recombinant erythropoietin increased the number of tumor-initiating cells in established breast cancer lines in vitro. Irradiation of breast cancer xenografts caused a phenotype conversion of non-stem breast cancer cells into induced breast cancer-initiating cells. This effect coincided with re-expression of the pluripotency factors c-Myc, Sox2, and Oct4 and was enhanced by recombinant erythropoietin. Hemoglobin levels were inversely correlated with serum erythropoietin levels, and the latter were correlated with disease stage. However, tumor sections revealed a negative correlation between serum erythropoietin levels and the number of ALDH1A3-positive cells, a marker for breast cancer-initiating cells.

conclusionsWe conclude that physiologically slow-rising serum erythropoietin levels in response to tumor-related or chemotherapy-induced anemia, as opposed to large doses of recombinant erythropoietin, do not increase the pool of breast cancer-initiating cells.

Indexed as

AdultAgedAged, 80 and overAldehyde OxidoreductasesAnemiaAnimalsAntineoplastic AgentsBreastBreast NeoplasmsCell Line, TumorErythropoietinFemaleHemoglobinsHumansMiceMice, Inbred NODaldehyde dehydrogenase (NAD(P)+)Aldehyde OxidoreductasesAntineoplastic AgentsEPO protein, humanErythropoietinHemoglobinsRecombinant ProteinsBreast cancer-initiating cellsErythropoietinRadiation therapy

Identifiers

PMID30700319
PMCPMC6354373
OpenAlexW2924534585

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.